pharmaphorum

SEPTEMBER 20, 2021

For the pharma industry, the pandemic’s changes were both abrupt and industry-altering, requiring companies to rapidly adapt their approaches to drug development and commercialisation. Analytics tools managed by the pharma sales team can be valuable for tracking physician preferences when developing your omnichannel approach.

Sales 97

Sales Marketing Pharma Companies Licensing 97

pharmaphorum

NOVEMBER 29, 2021

The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – is rumoured to be up for sale. It was billed at the time as a key tool to accelerate the development of new and innovative vaccines to combat some of the world’s most prevalent diseases, from discovery to licensed product.

Vaccination 100

Vaccination Vaccine Manufacturing Pharma Companies 100

pharmaphorum

FEBRUARY 12, 2021

The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.

Drugs 109

Drugs Sales Pharma Companies Marketing 109

pharmaphorum

MARCH 8, 2022

billion in sales last year. Low-cost rivals to multiple myeloma therapy Revlimid (lenalidomide) started to become available in Europe earlier this year, and have now been introduced in the US market by Teva and Natco Pharma, under the terms of a license agreed with Revlimid’s original developer Celgene.

Sales 52

Sales Marketing Pharma Companies Licensing 52

pharmaphorum

DECEMBER 22, 2021

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. Last year, it also signed a licensing deal with Dyno Therapeutics for its AAV capsid-based gene delivery technology focused on ocular diseases.

Gene Therapy 103

Gene Therapy Gene Licensing Licensing 103

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 65

Antibody Licensing Licensing Sales 65

Pharmaceutical Technology

AUGUST 1, 2022

As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning. If robust support comes from governments, pharma companies will grow in confidence about entering this area, and hopefully, a much-needed flurry of antibiotics will be developed.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e.

Life Science 98

Life Science Pharma Companies Sales Marketing 98

Fossil Remedies

AUGUST 21, 2019

It is an agreement between a franchiser which is typically a pharma manufacturing (or marketing) company where a franchisee is an individual entrepreneur or a small company that buys the license. Why is it a great idea to launch a pharma franchise? Are there any sales targets? GST copy issued by govt.

Pharma Companies 40

Pharma Companies Production Licensing Licensing 40

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

OCTOBER 7, 2021

The factory will be able to supply up to 500 million doses of mRNA shots a year, and cover the full spectrum of manufacturing from drug substance production through to full/finish and packaging, according to the company. According to the latest WHO data, just 4.4%

Vaccination 96

Vaccination Vaccine Manufacturing Packaging 96

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. But what steps can the smaller companies at the cutting edge take to make them acquisition-ready and maximise their value during this process?

Compliance 116

Compliance Regulation Manufacturing Licensing 116

pharmaphorum

JUNE 16, 2021

Enhertu has already been approved for third-line use in HER2-positive breast cancer as well as previously-treated HER2-posiitve gastric cancer, and analysts think peak sales could be north of $2 billion, if the ADC can move into earlier lines of therapy and other tumour types. The company plans to list on the NYSE with the AMAM ticker.

Sales 53

Sales Antibody Drugs Pharma Companies 53

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

pharmaphorum

NOVEMBER 23, 2021

Another $190 million is tied to a first commercial sale, and up to $590 million if it hits sales targets. Pharma companies have piled into the NASH space in recent years, lured by the promise of big rewards for the first drugs to treat a disease that afflicts millions of people around the world and is becoming more common.

Sales 52

Sales Drugs Trials RNA 52

Fossil Remedies

OCTOBER 23, 2019

He will examine the overall business concept and determine the ways to boost sales. You can team up with some establish pharma manufacturing company. The last and final step is to verify the license requirements. Once the company is launched, it is time to promote the brand by using every possible channel.

Manufacturing 67

Manufacturing Branding Pharma Companies Pharma Production 67

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Exelead was part of that success, helping to manufacture vaccine precursors for the Pfizer/BioNTech shot Comirnaty.

Vaccination 98

Vaccination Vaccine Manufacturing Life Science 98

pharmaphorum

DECEMBER 21, 2020

Each programme includes undisclosed upfront and milestone payments plus royalties on sales, with Merck indicating in a statement that it will be funding the research. Just a few weeks ago, Merck (known as MSD outside North America) paid $425 million to get hold of OncoImmune.

Immune Response 53

Immune Response Sales Antibody Pharma Companies 53

Creogenic Pharma

FEBRUARY 17, 2021

Our Pharma Franchise version relies on Monopoly rights, Real rates & no huge sale target. So, come and become a part of the Best PCD Pharma Company in TamilNadu. Valid Drug License No. Small-scale companies or distributors can also apply. No target of sales. About Tamil Nadu –. SEND ENQUIRY.

Production 52

Production Sales Pharma Companies Marketing 52

pharmaphorum

DECEMBER 16, 2022

Of significant interest to the pharma industry are the suggestions in the draft text that money granted for research on infectious diseases could include specifications on how eventual products could be marketed.

Vaccination 91

Vaccination Vaccine Production Licensing 91

pharmaphorum

NOVEMBER 23, 2022

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults with the bleeding disorder in the US. The post uniQure, CSL claim first okay for haemophilia B gene therapy appeared first on.

Gene Therapy 57

Gene Therapy Gene FDA Approval Trials 57

pharmaphorum

APRIL 19, 2022

RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 The company’s second drug candidate, RCI002, is focused on chronic pain. Everyone in our team is very valuable,” he said.

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52

pharmaphorum

SEPTEMBER 8, 2022

Big pharma has already noted its interest in the area, as seen in Novartis’ investments. Last year, the company signed two deals in quick succession, which saw it form a licensing deal worth $1.3 billion with Artios Pharma and with iTheranostics for a number of diagnostic radiopharmaceuticals.

Manufacturing 103

Manufacturing Development Drugs Antibody 103

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The post Lilly adds to pain pipeline with Asahi Kasei licensing deal appeared first on.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

MAY 14, 2021

“It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE. of global pharmaceutical sales, while the entire European market represents more than 20%.”. It’s important to remember that the UK market represents only 2.5% appeared first on.

Marketing 57

Marketing Regulation Medicine Life Science 57

Drug Discovery World

MARCH 29, 2023

The commission is looking to put more pressure on pharma companies to report such shortages, and to offer a drug’s marketing authorisation to another company before withdrawing it from the market. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

Drug Discovery World

OCTOBER 4, 2022

Several of the large pharma companies have recently re-entered the dementia field. Diseases such as PSP and FTD have no licensed and available treatments. But according to Erhardt, most are counting on antibody programs targeting beta amyloid or tau.

Development 52

Development In-Vivo Compound Screening Clinical Development 52

Pharma Business Blog

MARCH 16, 2022

Happy to share the following Article of Chemie Pharma Innovation with you (German only): [link]. Dr. Sandra Ragaz , Partner Leader Pharma & Life Science VAT Switzerland Tel: +41 58 792 44 69 sandra.ragaz@pwc.ch. Der Beitrag The Pharma Gamechanger erschien zuerst auf Welcome. Have a pleasant reading.

Life Science 52

Life Science Licensing Licensing Pharma Companies 52

pharmaphorum

APRIL 1, 2021

In the past couple of years, Turbine worked with a number of big pharma companies, including Bayer, and has also started building its own pipeline, including a target delivering new biological insight in PARP inhibitor resistance. “We There’s not really a well-developed ecosystem of biotech funding and spin-out companies.

Bioinformatics 107

Bioinformatics Drugs Development Scientist 107

XTalks

DECEMBER 29, 2022

Vertex is planning to submit a Biologics License Application (BLA) by the end of the first quarter of 2023 and the company says it is also on track to submit exa-cel to UK and European Union (EU) regulators by the end of the year. 4. Social Media Marketing.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

The Pharma Data

NOVEMBER 11, 2020

Lung Tx”) announced today an exclusive license agreement of LTI-01 , a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions , for the territory of Japan. Lung Tx will receive an upfront payment, milestone, and royalty payments based on product sales.

Licensing 40

Licensing Licensing Allergies Development 40

pharmaphorum

AUGUST 4, 2020

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock Exchange following the announcement, the highest they had been since 2015.

Drugs 91

Drugs Clinical Trials Clinical Trials Pharma Companies 91

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. million, compared to $1.1 million for the same period in 2022.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

DECEMBER 7, 2020

Having worked all around the world to supply medicines to developing markets, Dr Zulf Masters understands the biggest barrier for a pharma company entering these regions is a lack of understanding of their complexities. Developing market specialist Dr Zulf Masters OBE takes us through the nuances of being successful in this region.

Marketing 92

Marketing Regulation Production Medicine 92

XTalks

MARCH 22, 2023

While not a record-breaking deal at $17 billion, the buyout strengthened Pfizer’s injectables business unit with the company reporting an 11 percent increase in revenue the following year. More potential patients equal more prescriptions which equals higher sales and bigger profits.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Drug Discovery World

OCTOBER 7, 2022

TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out. companies to supplement their own R&D; most novel ideas stem from academia. Tony Hickson.

HR 52

HR Research Drugs Development 52